Nippon Shinyaku KK

4516

Equity

ISIN JP3717600005 / Valor 763041

Tokyo Stock Exchange (2024-11-20)

JPY 4,018.00-0.69%

Nippon Shinyaku KK
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Nippon Shinyaku KK is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products and functional food ingredients. The company focuses on providing innovative treatments in areas such as urology, hematology, and rare diseases, aiming to address unmet medical needs. With a commitment to improving patient outcomes, Nippon Shinyaku leverages its expertise in biotechnology and drug development to deliver effective therapeutic solutions. Additionally, the company produces functional food ingredients that contribute to health and wellness. Through its comprehensive approach to healthcare, Nippon Shinyaku strives to enhance the quality of life for patients and consumers.

Summarized from source with an LLMView SourceSector: Healthcare

Sales Revenue

In the first quarter of the fiscal year ending March 2025, Nippon Shinyaku KK reported sales revenue of 39,131 million yen. This represents an increase from the 37,012 million yen reported in the first quarter of the previous fiscal year. The company forecasts total sales revenue of 154,000 million yen for the entire fiscal year ending March 2025.

Operating Income

Nippon Shinyaku KK's operating income for the first quarter of the fiscal year ending March 2025 was 11,078 million yen. This is slightly lower than the 11,163 million yen reported in the same quarter of the previous fiscal year. The company projects an operating income of 32,000 million yen for the full fiscal year ending March 2025.

Net Income

The net income attributable to owners of the parent for Nippon Shinyaku KK in the first quarter of the fiscal year ending March 2025 was 10,264 million yen. This is an increase from the 8,749 million yen reported in the first quarter of the previous fiscal year. The company expects a net income of 29,000 million yen for the entire fiscal year ending March 2025.

R&D Expenses

Research and development expenses for Nippon Shinyaku KK in the first quarter of the fiscal year ending March 2025 amounted to 7,497 million yen. This is higher than the 5,911 million yen spent in the first quarter of the previous fiscal year. The company has forecasted R&D expenses to reach 32,400 million yen for the full fiscal year ending March 2025.

Cash Flows

For the first quarter of the fiscal year ending March 2025, Nippon Shinyaku KK reported a cash flow from operating activities of 7,004 million yen. Cash flow from investing activities was negative at △6,788 million yen, and cash flow from financing activities was also negative at △4,328 million yen. These figures indicate the company's ongoing investments and financial activities.

Summarized from source with an LLMView Source

Key figures

-25.1%1Y

-53.4%3Y

-59.7%5Y

Performance

42.0%1Y

34.4%3Y

34.0%5Y

Volatility